Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02489890 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CIK in Treating Patients With Bladder Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 22, 2016 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Jul 2015 to Feb 2016
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Chemotherapy is the main treatment method for patients with Bladder Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Bladder Cancer.
Trial Details
NCT Number NCT02489890
Lead Sponsor The First People's Hospital of Changzhou
Conditions
(from sponsor)		 Urinary Bladder Neoplasms
Related terms Urinary Bladder Neoplasms
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov